(2017) 35(Suppl. 4S):412. doi:10.1200/JCO.2017.35.4_suppl.412 34. Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dend ritic cell- based immunotherapy: state of the art and beyond. Clin Cancer Res. (2016) 22:1897–906.doi:10.1158/1078-0432.CCR-15-1399 35. vanWilligenWW,BloemendalM,GerritsenWR,SchreibeltG,deVries IJM, Bol KF. Dendritic cell cancer therapy: vaccinating the right patie nt at the righttime. FrontImmunol. (2018)9:2265.doi:10.3389/ﬁmmu.2018.02265 36. Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, et al. The feasibility and safety of immunotherapy with dendritic ce lls Frontiers in Immunology | www.frontiersin.org 14 August 2019 | Volume 10 | Article 1832 Bassani-Sternberg et al. Personalized Vaccine for Pancreatic Cancer loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer.